Lymphoma Cases Flashcards
Lymphoma dx
PE (waldeyer's ring) B sxs CBC w/ differential, CMP, LDH, uric acid Excisional biopsy needed (bone marrow, flow cytometry) Staging imaging (CT/PET) EF, PFTs Hep B Fertility counseling HIV
HL sxs
enlarging, rubbery, but not tender lymphadenopathy. Typically in the neck or chest. Can be accompanied by Fatigue FeverB Weight lossB Night sweatsB Pain with EtOH Symptoms of cytopenias Hepatosplenomegaly Pruritis
_______ is a rare cancer, but in young people with cancer, it is very common.
Hodgkin Lymphoma
malignant cell in HL
reed-sternberg
Reed sternberg is a ___ cell, some are ____+
B cell
CD20+
Bulk of HL tumor is
reactive tissue (background cells? = benign, but very prevalent)
Classical HL types and marker
Nodular sclerosis (grades I and II)
Lymphocyte-rich classical
Mixed cellularity
Lymphocyte depleted
These are CD30+
Non-classical HL type and marker
Nodular lymphocyte predominant
CD20+
HL staging
Ann arbor staging: I - single LN region II - One side of diaphragm III - both sides of diaphragm IV - disseminated
A - no systemic symptoms
B - fever, night sweats, weight loss
E - extralymphatic site
S - splenic site
HL treatment
intent to cure!
Localized favorable risk: ABVD x 2 then restage, involved field radiation
Stage III/IV disease: ABVD x 2 (restage then okay) -> ABVDx4 +/- XRT
ABVD x2 (restage but refractory) then intense chemo BEACOPP, autologous transplant
Late effects of therapy
Second malignancy (solid tumors ie lung and breast - risk continues to build, or leukemia - rare after 10-15 years)
Heart disease
Lung disease
Impaired fertility
HL markers
a. CD15+, CD30+, EBER+, CD20-, CD79a-, CD45-
b. CD5-, CD23-, CD19+, CD20+
c. CD5+, CD10-, CD20+, CD23-, cyclin D1+
d. CD5+, CD19+, CD20(dim), CD22−, CD23+, CD79b−
a. CD15+, CD30+, EBER+, CD20-, CD79a-, CD45- = HL
b. normal B cell
c. mantle
D. CLL
prognostics system for diffuse large b-cell lymphoma
IPI Prognostic factor: Age over 60 Stage III/IV ECOG PS 3 or 4 (more than ½ day resting) Elevated LDH Two or more extranodal sites
Score 0 or 1: ‘Good’ with predicted 4-year progression-free survival of 94% and overall survival of 94%.
Score 2: ‘Intermediate’ with predicted 4-year progression-free survival of 80% and overall survival of 79%.
Score 3, 4 or 5: ‘Poor’ with predicted 4-year progression-free survival of 53% and overall survival of 55%
prototype aggressive NHL for adults
Diffuse large b-cell lymphoma
tx DLBL
R-CHOP